January 17 at noon EST
Dr. Bob Spiegel, Chief Medical Offier at PTC Therapeutics will present information about the study design and timeline for the upcoming Phase 3 confirmatory study of ataluren in Duchenne muscular dystrophy.
Questions can be submitted until noon on Monday, January 14, by emailing info@ParentProjectMD.org (please put "Ataluren Webinar” as the subjec…
You can share this event in two ways…
Share this link:
Send it with your computer's email program: Email this